Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of sublingual Dermatophagoides mix immunotherapy for dust mite allergic rhinitis
2025-521522-15-00Phase 2Authorised
- Sponsor
- Asacpharma
- Start
- Sep 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of dermatophagoides pteronyssinus + dermatophagoides farinae allergen immunotherapy in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Asacpharma. Primary endpoint: Response to nasal provocation test. Planned start Sep 2025; status: authorised.
02
Drugs
dermatophagoides pteronyssinus + dermatophagoides farinae allergen immunotherapy
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2025-521522-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521522-15-00.